Galapagos NV Receives Transparency Notification and 13D Filing from Tang Capital

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) has received a transparency notification and a 13D filing from Tang Capital.

In compliance with Belgian transparency laws, Galapagos was notified on February 14, 2025, by Tang Capital Management, LLC, and its associated entities. These entities include TCP (Tang Capital Partners, LP), TCPI (Tang Capital Partners International, LP), and TCP III (Tang Capital Partners III, Inc.), which have reported holding a significant number of Galapagos shares.

Specifically, TCP and TCPI together hold 887,227 ordinary shares, while TCP, TCPI, and TCP III possess a total of 2,436,180 American Depository Receipts (ADRs), each of which represents one ordinary share. Altogether, this amounts to 3,323,407 voting rights in Galapagos, equating to 5.04% of the company’s total outstanding shares, which currently stand at 65,897,071. This acquisition meant that they surpassed the 5% voting rights threshold on February 7, 2025.

The notification further explains the organizational structure and voting powers within Tang Capital. Mr. Kevin Tang is noted as the manager of TCM and serves as CEO of TCP III and Tang Capital Partners IV, Inc. Accordingly, he shares control over these voting rights with the other associated entities. This information is crucial as it indicates the shared operational dynamics and voting capabilities among these firms.

Additionally, on February 14, 2025, TCM filed a Schedule 13D with the SEC, which reveals that it beneficially owns 4,910,525 of Galapagos' voting rights. This consists of 966,119 ordinary shares and 2,544,406 ADRs, as well as 1,400,000 ADRs under call option contracts set to expire on February 21, 2025. The total percentage of voting rights represented through these holdings stands at approximately 7.5%.

The filing also mentions potential obligations for Tang Capital entities. They face commitments to buy 1,043,500 shares by way of put options, which will also expire on February 21, 2025. Furthermore, they have obligations to sell 200,000 shares ahead of call option contracts that conclude on April 17, 2025.

For those seeking more detailed information, the complete transparency notification and Schedule 13D can be found on the official Galapagos website.

About Galapagos

Galapagos NV is a biotechnology entity focused on enhancing patient outcomes through innovative scientific advancements. Operating in both Europe and the U.S., the company aims to address significant medical needs by merging cutting-edge science with collaborative efforts. Their commitment is to develop an extensive array of high-quality medicine aimed at changing lives. With capabilities that span from research to patient care, Galapagos is dedicated to challenging conventional medical practices and delivering meaningful results for its patients and shareholders. For further information, individuals can visit Galapagos' official website or follow them on platforms like LinkedIn.

Contact Information

Media inquiries:
Srikant Ramaswami
+1 412 699 0359

Marieke Vermeersch
+32 479 490 603
[email protected]

Investor inquiries:
Srikant Ramaswami
+1 412 699 0359

Sandra Cauwenberghs
+32 495 58 46 63

[email protected]

Galapagos, notification, finance